ARTA
TRIL

A.R.T. Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

A.R.T. Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26,593
Closed -$27K – 1203
2019
Q4 		$27K Buy
+26,593
New +$10.2K ﹤0.01% 1274
2017
Q2 		– Sell
-23,225
Closed -$143K – 1836
2017
Q1 		$143K Buy
+23,225
New +$136K 0.01% 1226
2015
Q3 		– Sell
-19,483
Closed -$425K – 1700
2015
Q2 		$425K Buy
19,483
+4,003
+26% +$91.3K 0.01% 1050
2015
Q1 		$313K Buy
+15,480
New +$228K 0.01% 1096

Other funds holding TRIL

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

A.R.T. Advisors's TRIL Position: Q1 2020 in Review

A.R.T. Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2020, closing a stake of 26,593 shares — an estimated $27K sold.

A.R.T. Advisors first reported a position in TRIL in Q1 2015 and held it in 4 quarters. The position peaked at $425K in Q2 2015. 65 funds tracked by Wall St. Rank hold TRIL as of Q1 2020.

  • A.R.T. Advisors reported no remaining Trillium Therapeutics Inc. position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 26,593 Trillium Therapeutics Inc. shares in Q1 2020, an estimated $27K.
  • A.R.T. Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2015 and held it in 4 quarters.
  • A.R.T. Advisors's Trillium Therapeutics Inc. position peaked at $425K in Q2 2015.
  • 65 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.